Posted by Michael Wonder on 05 Oct 2019
Galderma receives FDA approval for Aklief (trifarotene) 0.005% cream, the first new retinoid molecule for the treatment of acne in over 20 years
4 October 2019 - Next-generation treatment is first option studied and proven effective in both facial and truncal acne.
Galderma announced today that the U.S. FDA approved Aklief (trifarotene) 0.005% cream for the topical treatment of acne. AKLIEF Cream is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin.
Trifarotene is the first new retinoid molecule to receive U.S. FDA approval for the treatment of acne in more than 20 years. Aklief cream is the first topical treatment specifically studied and proven to treat both facial (forehead, cheeks, nose and chin) and truncal (chest, shoulders and back) acne, offering healthcare professionals and acne patients another treatment option.
The FDA approval of Aklief cream is supported by data from the two pivotal Phase 3 clinical trials of once-daily Aklief cream in patients with moderate acne on the face and trunk.
